Evidence map›Paper›PMID 40968189›Full record

ArticleDiabetologia2025

Trends in type 1 diabetes incidence between 2007 and 2023 and their association with SARS-CoV-2 infection in a population-based matched cohort study among individuals under 30 years old in Sweden.

Dominik Dietler, Jonas Björk, Elsa Palmkvist, Annelie Carlsson

Abstract read
In one paragraph

Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Twenty-five years of pediatric type 1 diabetes in Serbia: Trends in age at diagnosis, seasonal variation, and the proportion of diabetic ketoacidosis before, during, and after the COVID-19 pandemic.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dominik DietlerDivision of Occupational and Environmental Medicine, Lund University, Lund, Sweden. dominik.dietler@med.lu.se.ORCID http://orcid.org/0000-0001-9629-125X
Jonas BjörkDivision of Occupational and Environmental Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-1883-2000
Elsa PalmkvistDepartment of Clinical Sciences, Department of Pediatrics, Skåne University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-8636-8804
Annelie CarlssonDepartment of Clinical Sciences, Department of Pediatrics, Skåne University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-5608-3437

Funding

Riksbankens Jubileumsfond RIK21-0004Stiftelsen för Strategisk Forskning IRC15-0067Vetenskapsrådet 2022-06358VINNOVA 2021-02648
6 · The paper itself

Abstract

aims/hypothesisThe incidence of type 1 diabetes increased during the pandemic in various countries. SARS-CoV-2 infections may trigger the development of type 1 diabetes, but the evidence is inconclusive. This study aimed to assess trends in type 1 diabetes incidence between 2007 and 2023, and to quantify the association between SARS-CoV-2 infections and the risk for developing type 1 diabetes.

methodsThe study included all individuals under 30 years old registered in Sweden. Deviations in type 1 diabetes incidence from pre-pandemic trends (2007-2019) were assessed for each pandemic year (2020-2023) using Poisson regression. The effect of SARS-CoV-2 infections was assessed using Cox proportional hazards models in a cohort of infected individuals with five control individuals from the infection date of the case, matched by birth year, sex and region.

resultsCompared with the predicted linear trend, type 1 diabetes incidence increased by 12% during 2021 (incidence rate ratio [IRR] 1.12; 95% CI 1.06, 1.19) and 9% during 2022 (IRR 1.09; 95% CI 1.02, 1.16), but reverted to pre-pandemic trends in 2023. Overall, the adjusted HR for developing type 1 diabetes after SARS-CoV-2 infection was 0.96 (95% CI 0.79, 1.16). Children between 5 and 10 years old were more likely to develop type 1 diabetes within the first 28 days after infection (HR 2.68; 95% CI 1.22, 5.89), although their hazard over the whole follow-up period was not increased. CONCLUSIONS/

interpretationSweden, with its non-restrictive pandemic response, saw a transient increase in type 1 diabetes incidence that was only partially associated with SARS-CoV-2 infections. Other explanations should be investigated, including environmental and lifestyle factors.

Indexed as

COVID-19Diabetes Mellitus, Type 1AdolescentAdultChildChild, PreschoolCohort StudiesFemaleHumansIncidenceInfantMalePandemicsProportional Hazards ModelsRisk FactorsSARS-CoV-2COVID-19EpidemiologyType 1 diabetesViral disease

Identifiers

PMID40968189
PMCPMC12594641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.